{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma%2C+Sarcomatous&page=3", "query": { "condition": "Glioma, Sarcomatous", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 447, "total_pages": 45, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma%2C+Sarcomatous&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma%2C+Sarcomatous&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T23:52:02.197Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003185", "title": "Biological Therapy in Treating Patients With Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "autologous tumor cell vaccine", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "tumor-draining lymph node lymphocyte therapy", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "1997-08", "completion_date": "1998-07", "has_results": false, "last_update_posted_date": "2013-12-04", "last_synced_at": "2026-10-07T23:52:02.197Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003185" }, { "nct_id": "NCT00423735", "title": "Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Neoplasm" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2007-01-24", "completion_date": "2018-09-04", "has_results": true, "last_update_posted_date": "2019-07-24", "last_synced_at": "2026-10-07T23:52:02.197Z", "location_count": 184, "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 144 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Auburn", "state": "California" }, { "city": "Cameron Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00423735" }, { "nct_id": "NCT00612638", "title": "Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "Temodar, O6-BG, and Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2005-01", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-10-07T23:52:02.197Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00612638" }, { "nct_id": "NCT02743078", "title": "Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Glioma", "Gliosarcoma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "TTFields Therapy", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "RTOG Foundation, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 3, "start_date": "2017-05-09", "completion_date": "2019-10-15", "has_results": true, "last_update_posted_date": "2021-06-02", "last_synced_at": "2026-10-07T23:52:02.197Z", "location_count": 11, "location_summary": "La Jolla, California • Orange, California • Miami, Florida + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02743078" }, { "nct_id": "NCT01931098", "title": "Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme", "Gliosarcoma", "Brain Neoplasms", "Central Nervous System Neoplasms" ], "interventions": [ { "name": "topotecan", "type": "DRUG" }, { "name": "pazopanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2015-12-10", "completion_date": "2019-09-12", "has_results": true, "last_update_posted_date": "2025-08-11", "last_synced_at": "2026-10-07T23:52:02.197Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01931098" }, { "nct_id": "NCT00019071", "title": "Chemotherapy Followed by Radiation Therapy in Treating Patients With Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "chemotherapy", "type": "DRUG" }, { "name": "cladribine", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1995-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-29", "last_synced_at": "2026-10-07T23:52:02.197Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019071" }, { "nct_id": "NCT05363826", "title": "Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme of Brain", "Glioma, Sarcomatous" ], "interventions": [ { "name": "photochemotherapy using 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester(Photobac®)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Photolitec LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-04-11", "completion_date": "2026-05", "has_results": false, "last_update_posted_date": "2023-04-13", "last_synced_at": "2026-10-07T23:52:02.197Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05363826" }, { "nct_id": "NCT03911388", "title": "HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms, Brain", "Glioblastoma Multiforme", "Glioblastoma of Cerebellum", "Neoplasms", "Astrocytoma", "Astrocytoma, Cerebellar", "Neuroectodermal Tumors", "Neuroectodermal Tumors, Primitive", "Cerebellar PNET, Childhood", "Cerebellar Neoplasms", "Cerebellar Neoplasms, Primary", "Cerebellar Neoplasm, Malignant", "Cerebellar Neoplasm Malignant Primary", "Neoplasm Metastases", "Neoplasm Malignant", "Neoplasms, Neuroepithelial", "Neoplasms, Germ Cell and Embryonal", "Neoplasms by Histologic Type", "Neoplasms, Glandular and Epithelial", "Neoplasms, Nerve Tissue", "Central Nervous System Neoplasms, Primary", "Central Nervous System Neoplasms, Malignant", "Nervous System Neoplasms", "Neoplasms by Site", "Brain Diseases", "Central Nervous System Diseases", "Nervous System Diseases", "Medulloblastoma Recurrent", "HSV", "Virus", "Pediatric Brain Tumor", "Nervous System Cancer", "Primitive Neuroectodermal Tumor (PNET) of Cerebellum" ], "interventions": [ { "name": "G207", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "36 Months", "maximum_age": "22 Years", "sex": "ALL", "summary": "36 Months to 22 Years" }, "enrollment_count": 24, "start_date": "2019-09-12", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-07T23:52:02.197Z", "location_count": 3, "location_summary": "Birmingham, Alabama • St Louis, Missouri • Houston, Texas", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03911388" }, { "nct_id": "NCT05857969", "title": "Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Large Cell Lymphoma", "Refractory Childhood Acute Lymphoblastic Leukemia", "Refractory Childhood Hodgkin Lymphoma", "Refractory Childhood Malignant Germ Cell Neoplasm", "Recurrent Childhood Brain Tumor", "Recurrent Childhood Brainstem Glioma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Gliosarcoma", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Refractory Childhood Malignant Solid Neoplasm", "Recurrent Childhood Malignant Solid Neoplasm", "Recurrent Childhood Malignant Neoplasm", "Refractory Childhood Malignant Neoplasm" ], "interventions": [ { "name": "Functional Precision Medicine", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Florida International University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Day to 21 Years" }, "enrollment_count": 65, "start_date": "2023-02-22", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-07T23:52:02.197Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05857969" }, { "nct_id": "NCT00777686", "title": "Measuring Non-Enhancing Glioblastoma Progression", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Brain Tumor", "Glioblastoma" ], "interventions": [ { "name": "MRI/MRS Scan", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2008-08", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2012-03-30", "last_synced_at": "2026-10-07T23:52:02.197Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00777686" } ] }